Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.
Identifieur interne : 002650 ( Ncbi/Merge ); précédent : 002649; suivant : 002651Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.
Auteurs : Zhongyu Zhu [États-Unis] ; Ponraj Prabakaran ; Weizao Chen ; Christopher C. Broder ; Rui Gong ; Dimiter S. DimitrovSource :
- Virologica Sinica [ 1995-820X ] ; 2013.
Descripteurs français
- KwdFr :
- Animaux, Anticorps monoclonaux (immunologie), Anticorps monoclonaux (usage thérapeutique), Humains, Maladies virales (), Maladies virales (immunologie), Maladies virales (traitement médicamenteux), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (immunologie), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (pathogénicité), Virus Hendra (immunologie), Virus Hendra (pathogénicité), Virus Nipah (immunologie), Virus Nipah (pathogénicité), Virus du SRAS (immunologie), Virus du SRAS (pathogénicité).
- MESH :
- immunologie : Anticorps monoclonaux, Maladies virales, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Virus Hendra, Virus Nipah, Virus du SRAS.
- pathogénicité : VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Virus Hendra, Virus Nipah, Virus du SRAS.
- traitement médicamenteux : Maladies virales.
- usage thérapeutique : Anticorps monoclonaux.
- Animaux, Humains, Maladies virales.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (therapeutic use), HIV-1 (immunology), HIV-1 (pathogenicity), Hendra Virus (immunology), Hendra Virus (pathogenicity), Humans, Nipah Virus (immunology), Nipah Virus (pathogenicity), SARS Virus (immunology), SARS Virus (pathogenicity), Virus Diseases (drug therapy), Virus Diseases (immunology), Virus Diseases (prevention & control).
- MESH :
- chemical , immunology : Antibodies, Monoclonal.
- chemical , therapeutic use : Antibodies, Monoclonal.
- drug therapy : Virus Diseases.
- immunology : HIV-1, Hendra Virus, Nipah Virus, SARS Virus, Virus Diseases.
- pathogenicity : HIV-1, Hendra Virus, Nipah Virus, SARS Virus.
- prevention & control : Virus Diseases.
- Animals, Humans.
Abstract
More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.
DOI: 10.1007/s12250-013-3313-x
PubMed: 23575729
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001222
- to stream PubMed, to step Curation: 001222
- to stream PubMed, to step Checkpoint: 001166
Links to Exploration step
pubmed:23575729Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.</title><author><name sortKey="Zhu, Zhongyu" sort="Zhu, Zhongyu" uniqKey="Zhu Z" first="Zhongyu" last="Zhu">Zhongyu Zhu</name><affiliation wicri:level="2"><nlm:affiliation>Protein Interactions Group, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Protein Interactions Group, National Cancer Institute, National Institutes of Health, Frederick, MD 21702</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Prabakaran, Ponraj" sort="Prabakaran, Ponraj" uniqKey="Prabakaran P" first="Ponraj" last="Prabakaran">Ponraj Prabakaran</name></author><author><name sortKey="Chen, Weizao" sort="Chen, Weizao" uniqKey="Chen W" first="Weizao" last="Chen">Weizao Chen</name></author><author><name sortKey="Broder, Christopher C" sort="Broder, Christopher C" uniqKey="Broder C" first="Christopher C" last="Broder">Christopher C. Broder</name></author><author><name sortKey="Gong, Rui" sort="Gong, Rui" uniqKey="Gong R" first="Rui" last="Gong">Rui Gong</name></author><author><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S" last="Dimitrov">Dimiter S. Dimitrov</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23575729</idno><idno type="pmid">23575729</idno><idno type="doi">10.1007/s12250-013-3313-x</idno><idno type="wicri:Area/PubMed/Corpus">001222</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001222</idno><idno type="wicri:Area/PubMed/Curation">001222</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001222</idno><idno type="wicri:Area/PubMed/Checkpoint">001166</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001166</idno><idno type="wicri:Area/Ncbi/Merge">002650</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.</title><author><name sortKey="Zhu, Zhongyu" sort="Zhu, Zhongyu" uniqKey="Zhu Z" first="Zhongyu" last="Zhu">Zhongyu Zhu</name><affiliation wicri:level="2"><nlm:affiliation>Protein Interactions Group, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Protein Interactions Group, National Cancer Institute, National Institutes of Health, Frederick, MD 21702</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Prabakaran, Ponraj" sort="Prabakaran, Ponraj" uniqKey="Prabakaran P" first="Ponraj" last="Prabakaran">Ponraj Prabakaran</name></author><author><name sortKey="Chen, Weizao" sort="Chen, Weizao" uniqKey="Chen W" first="Weizao" last="Chen">Weizao Chen</name></author><author><name sortKey="Broder, Christopher C" sort="Broder, Christopher C" uniqKey="Broder C" first="Christopher C" last="Broder">Christopher C. Broder</name></author><author><name sortKey="Gong, Rui" sort="Gong, Rui" uniqKey="Gong R" first="Rui" last="Gong">Rui Gong</name></author><author><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S" last="Dimitrov">Dimiter S. Dimitrov</name></author></analytic><series><title level="j">Virologica Sinica</title><idno type="eISSN">1995-820X</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (immunology)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>HIV-1 (immunology)</term><term>HIV-1 (pathogenicity)</term><term>Hendra Virus (immunology)</term><term>Hendra Virus (pathogenicity)</term><term>Humans</term><term>Nipah Virus (immunology)</term><term>Nipah Virus (pathogenicity)</term><term>SARS Virus (immunology)</term><term>SARS Virus (pathogenicity)</term><term>Virus Diseases (drug therapy)</term><term>Virus Diseases (immunology)</term><term>Virus Diseases (prevention & control)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps monoclonaux (immunologie)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Humains</term><term>Maladies virales ()</term><term>Maladies virales (immunologie)</term><term>Maladies virales (traitement médicamenteux)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (immunologie)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (pathogénicité)</term><term>Virus Hendra (immunologie)</term><term>Virus Hendra (pathogénicité)</term><term>Virus Nipah (immunologie)</term><term>Virus Nipah (pathogénicité)</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (pathogénicité)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Maladies virales</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Virus Hendra</term><term>Virus Nipah</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV-1</term><term>Hendra Virus</term><term>Nipah Virus</term><term>SARS Virus</term><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>HIV-1</term><term>Hendra Virus</term><term>Nipah Virus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Virus Hendra</term><term>Virus Nipah</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies virales</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Maladies virales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23575729</PMID><DateCompleted><Year>2013</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1995-820X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Virologica Sinica</Title><ISOAbbreviation>Virol Sin</ISOAbbreviation></Journal><ArticleTitle>Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.</ArticleTitle><Pagination><MedlinePgn>71-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12250-013-3313-x</ELocationID><Abstract><AbstractText>More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Zhongyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Protein Interactions Group, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prabakaran</LastName><ForeName>Ponraj</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Weizao</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Broder</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Rui</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Dimitrov</LastName><ForeName>Dimiter S</ForeName><Initials>DS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01CO12400</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-CO-12400</GrantID><Acronym>CO</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Virol Sin</MedlineTA><NlmUniqueID>101514185</NlmUniqueID><ISSNLinking>1995-820X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045404" MajorTopicYN="N">Hendra Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045405" MajorTopicYN="N">Nipah Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>02</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>03</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23575729</ArticleId><ArticleId IdType="doi">10.1007/s12250-013-3313-x</ArticleId><ArticleId IdType="pmc">PMC7090799</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Mol Biol. 2012 Jan 13;415(2):393-405</Citation><ArticleIdList><ArticleId IdType="pubmed">22198408</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Biotechnol. 2008 Dec;9(6):423-30</Citation><ArticleIdList><ArticleId IdType="pubmed">19075682</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Jan;80(2):891-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16378991</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2004 Feb 17;43(6):1410-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14769016</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2009 May 15;388(4):815-23</Citation><ArticleIdList><ArticleId IdType="pubmed">19324051</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2009 Dec 18;390(3):404-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19748484</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2009 Nov 20;326(5956):1123-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19965434</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2012 Sep 21;37(3):412-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22999947</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(8):e42288</Citation><ArticleIdList><ArticleId IdType="pubmed">22879932</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Med Virol. 2012 Jan;22(1):2-17</Citation><ArticleIdList><ArticleId IdType="pubmed">21905149</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Struct Mol Biol. 2008 Jun;15(6):567-72</Citation><ArticleIdList><ArticleId IdType="pubmed">18488039</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2011 Aug 12;333(6044):850-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21798894</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2010 May;120(5):1663-73</Citation><ArticleIdList><ArticleId IdType="pubmed">20389023</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Immunol. 2011 Jun;23(3):383-90</Citation><ArticleIdList><ArticleId IdType="pubmed">21524897</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17121-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18957538</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2005 Sep 29;437(7059):764-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16193056</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2009 Aug;16(8):1132-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19553554</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2008;3(12):e3942</Citation><ArticleIdList><ArticleId IdType="pubmed">19079604</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2010 Jun 5;401(2):228-35</Citation><ArticleIdList><ArticleId IdType="pubmed">20304456</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2012;8(5):e1002705</Citation><ArticleIdList><ArticleId IdType="pubmed">22615565</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Sep;78(17):9233-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15308718</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2008 Jul 10;454(7201):177-82</Citation><ArticleIdList><ArticleId IdType="pubmed">18615077</ArticleId></ArticleIdList></Reference><Reference><Citation>BioDrugs. 2012 Jun 1;26(3):143-62</Citation><ArticleIdList><ArticleId IdType="pubmed">22462520</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Jul;3(7):e237</Citation><ArticleIdList><ArticleId IdType="pubmed">16796401</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2012 Jan 27;417(4):1164-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22226962</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2009 Oct;5(10):e1000642</Citation><ArticleIdList><ArticleId IdType="pubmed">19888339</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2011 Mar 31;117(13):3559-68</Citation><ArticleIdList><ArticleId IdType="pubmed">21292773</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2013 Jan 5;435(1):46-56</Citation><ArticleIdList><ArticleId IdType="pubmed">23217615</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2004 Aug;10(8):871-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15247913</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Mol Biol. 2012;890:219-32</Citation><ArticleIdList><ArticleId IdType="pubmed">22688770</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2012 Sep 14;337(6100):1343-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22878502</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Sep 16;309(5742):1864-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16166518</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2006 Mar 17;357(1):82-99</Citation><ArticleIdList><ArticleId IdType="pubmed">16426633</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2008 Dec;7(12):1001-12</Citation><ArticleIdList><ArticleId IdType="pubmed">18989337</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2012 May 07;30(5):423-33</Citation><ArticleIdList><ArticleId IdType="pubmed">22565972</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1996 Feb;70(2):1100-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8551569</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(4):e36192</Citation><ArticleIdList><ArticleId IdType="pubmed">22558378</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2012 Sep;4(9):1619-50</Citation><ArticleIdList><ArticleId IdType="pubmed">23170176</ArticleId></ArticleIdList></Reference><Reference><Citation>Protein Eng Des Sel. 2012 Mar;25(3):107-17</Citation><ArticleIdList><ArticleId IdType="pubmed">22240293</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2012 Dec;86(24):13467-74</Citation><ArticleIdList><ArticleId IdType="pubmed">23035224</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Res Notes. 2011 Oct 12;4:404</Citation><ArticleIdList><ArticleId IdType="pubmed">21992227</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2011 Nov;85(21):11401-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21880764</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2011 Oct 19;3(105):105ra103</Citation><ArticleIdList><ArticleId IdType="pubmed">22013123</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Microbiol. 2006 Jan;4(1):23-35</Citation><ArticleIdList><ArticleId IdType="pubmed">16357858</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2013 Jan 15;207(2):319-22</Citation><ArticleIdList><ArticleId IdType="pubmed">23125446</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2010 Jul 9;400(2):155-70</Citation><ArticleIdList><ArticleId IdType="pubmed">20450918</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2008 Mar 15;197(6):846-53</Citation><ArticleIdList><ArticleId IdType="pubmed">18271743</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Microbiol. 2009 Mar;7(3):226-36</Citation><ArticleIdList><ArticleId IdType="pubmed">19198616</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(11):e50366</Citation><ArticleIdList><ArticleId IdType="pubmed">23185609</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2006 May;6(5):343-57</Citation><ArticleIdList><ArticleId IdType="pubmed">16622479</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Immunol. 2011 Nov;141(2):218-27</Citation><ArticleIdList><ArticleId IdType="pubmed">21925951</ArticleId></ArticleIdList></Reference><Reference><Citation>MAbs. 2009 Jan-Feb;1(1):26-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20046570</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2012 Jul 20;3:215</Citation><ArticleIdList><ArticleId IdType="pubmed">22833745</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbes Infect. 2009 Nov;11(13):1029-36</Citation><ArticleIdList><ArticleId IdType="pubmed">19651232</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):9953-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18632560</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801</Citation><ArticleIdList><ArticleId IdType="pubmed">15642942</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(3):e33298</Citation><ArticleIdList><ArticleId IdType="pubmed">22438910</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2706-11</Citation><ArticleIdList><ArticleId IdType="pubmed">14981267</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Nov 11;310(5750):1025-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16284180</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2006 Jun 9;281(23):15829-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16597622</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Microbiol. 2004 Sep;2(9):695-703</Citation><ArticleIdList><ArticleId IdType="pubmed">15372080</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2009 Apr 10;324(5924):246-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19251591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Mar 21;373(9668):1033-40</Citation><ArticleIdList><ArticleId IdType="pubmed">19304016</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2006 Nov 10;281(45):34610-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16954221</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2000 Mar 3;287(5458):1664-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10698744</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2009 Dec;1(3):802-17</Citation><ArticleIdList><ArticleId IdType="pubmed">21994570</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2010 Feb;2(2):547-565</Citation><ArticleIdList><ArticleId IdType="pubmed">21755021</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1998 Jun 18;393(6686):648-59</Citation><ArticleIdList><ArticleId IdType="pubmed">9641677</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2005 May;11(5):522-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15852016</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2009 Sep 18;387(2):387-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19615335</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Microbiol. 2012 Nov;20(11):532-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22981828</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunotherapy. 2012 Feb;4(2):175-86</Citation><ArticleIdList><ArticleId IdType="pubmed">22339460</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1757-65</Citation><ArticleIdList><ArticleId IdType="pubmed">11788027</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2008 Jan 4;375(1):202-16</Citation><ArticleIdList><ArticleId IdType="pubmed">18005986</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2004 Mar;42(3):1250-3</Citation><ArticleIdList><ArticleId IdType="pubmed">15004085</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2012 Sep;86(17):9113-21</Citation><ArticleIdList><ArticleId IdType="pubmed">22696652</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Mol Biol. 2012;899:1-26</Citation><ArticleIdList><ArticleId IdType="pubmed">22735943</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14216-21</Citation><ArticleIdList><ArticleId IdType="pubmed">21825125</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Microbiol. 2012 Aug 02;3:277</Citation><ArticleIdList><ArticleId IdType="pubmed">22876240</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1993 Nov;67(11):6642-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7692082</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2012 Jun 1;287(23):19399-408</Citation><ArticleIdList><ArticleId IdType="pubmed">22518843</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2005 May 25;336(1):70-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15866072</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2010 May 15;184(10 ):5696-704</Citation><ArticleIdList><ArticleId IdType="pubmed">20404276</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Struct Mol Biol. 2009 Mar;16(3):265-73</Citation><ArticleIdList><ArticleId IdType="pubmed">19234466</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2012 Apr;4(4):447-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22590681</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Mol Ther. 2005 Apr;7(2):151-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15844623</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Biol Ther. 2009 Mar;9(3):355-68</Citation><ArticleIdList><ArticleId IdType="pubmed">19216624</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2003 Mar;9(3):269-77</Citation><ArticleIdList><ArticleId IdType="pubmed">12612576</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1994 Nov 11;266(5187):1024-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7973652</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12123-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17620608</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepatology. 2012 Feb;55(2):364-72</Citation><ArticleIdList><ArticleId IdType="pubmed">21953761</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2007 Dec;25(12):1421-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18066039</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2006 Feb;5(2):147-59</Citation><ArticleIdList><ArticleId IdType="pubmed">16424916</ArticleId></ArticleIdList></Reference><Reference><Citation>MAbs. 2010 May-Jun;2(3):347-56</Citation><ArticleIdList><ArticleId IdType="pubmed">20400863</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18950-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20956322</ArticleId></ArticleIdList></Reference><Reference><Citation>MBio. 2012 Nov 20;3(6):null</Citation><ArticleIdList><ArticleId IdType="pubmed">23170002</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Apr;78(7):3325-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15016854</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Mol Pathol. 2012 Dec;93(3):399-407</Citation><ArticleIdList><ArticleId IdType="pubmed">23036472</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2005 Sep;77(1):83-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16032715</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2005 Feb 15;191(4):507-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15655773</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Jul 9;361(2):135-44</Citation><ArticleIdList><ArticleId IdType="pubmed">19587338</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2011 Aug 12;333(6044):843-50</Citation><ArticleIdList><ArticleId IdType="pubmed">21737702</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2005 Jul 22;333(1):186-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15939399</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs. 1999 Aug;58(2):305-11; discussion 312-3</Citation><ArticleIdList><ArticleId IdType="pubmed">10473022</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><noCountry><name sortKey="Broder, Christopher C" sort="Broder, Christopher C" uniqKey="Broder C" first="Christopher C" last="Broder">Christopher C. Broder</name><name sortKey="Chen, Weizao" sort="Chen, Weizao" uniqKey="Chen W" first="Weizao" last="Chen">Weizao Chen</name><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S" last="Dimitrov">Dimiter S. Dimitrov</name><name sortKey="Gong, Rui" sort="Gong, Rui" uniqKey="Gong R" first="Rui" last="Gong">Rui Gong</name><name sortKey="Prabakaran, Ponraj" sort="Prabakaran, Ponraj" uniqKey="Prabakaran P" first="Ponraj" last="Prabakaran">Ponraj Prabakaran</name></noCountry><country name="États-Unis"><region name="Maryland"><name sortKey="Zhu, Zhongyu" sort="Zhu, Zhongyu" uniqKey="Zhu Z" first="Zhongyu" last="Zhu">Zhongyu Zhu</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002650 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002650 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:23575729
|texte= Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:23575729" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |